Authoritative reporting on FDA, EMA, and global regulatory decisions — with the expert analysis to understand what each development means for your approvals, strategy, and compliance.
Regulatory teams can’t afford to simply react — they need to anticipate, influence, and lead. Pink Sheet delivers authoritative, in-depth analysis direct from the voices shaping policy decisions.
Coverage that explains the context, rationale, and likely consequences of regulatory decisions from FDA, EMA, MHRA, and beyond.
Direct interviews with FDA commissioners, CDER/CBER leadership, EMA officials, and industry leaders — not just press releases.
Nearly a century of trusted reporting, with Pink Sheet reporters recognized as domain experts and regular contributors at industry and government events.
Unlike headline-driven news outlets, Pink Sheet delivers authoritative, in-depth analysis of policy developments and regulatory decisions — direct from the voices shaping them.
Pink Sheet’s reporters have direct access to policymakers, advisory committees, and industry working groups — providing intelligence unavailable from any other source.
Pink Sheet’s depth goes beyond reporting decisions to helping regulatory and policy teams understand what each development means for their strategy, submissions, and stakeholder relationships.
Years trusted by regulatory professionals worldwide
Countries with in-house reporters and analysts
In-person conferences covered on average each month
Articles published annually for subscribers
In-depth coverage of inspection trends, GCP guidance, and quality standards shaping trial conduct and regulatory submissions.
How reimbursement frameworks, health technology assessments, and pricing policies interact with regulatory decisions globally.
Accelerated approval, breakthrough designation, orphan drug, and other special pathway developments tracked and analyzed.
Detailed analysis of key drug applications moving through FDA and global review, including advisory committee coverage.
Side-by-side analysis of regulatory approaches across the US, EU, UK, Japan, China, and other key markets.
Exclusive access to FDA commissioners, CDER/CBER leadership, EMA officials, and legislative staff for strategic perspective.
Pink Sheet’s unmatched access to regulators and policymakers means coverage often reflects signals and thinking that have not yet been made public. Regulatory teams use this intelligence to anticipate shifts in agency position, not just respond to them after the fact.
Pink Sheet’s analysis connects regulatory policy to commercial, access, and submission planning — giving regulatory, legal, and market access teams a shared intelligence base to align on risk, timelines, and stakeholder engagement strategies.
Pink Sheet’s suite of regulatory trackers covers FDA, EMA, and other agencies, monitoring submission timelines, advisory committee votes, approval designations, and CRLs so nothing falls through the cracks.
VPs and heads of regulatory affairs use Pink Sheet to anticipate agency actions, track submissions, and align internal teams on approval strategy.
Public affairs and government relations professionals use Pink Sheet to monitor policy developments and prepare for regulatory engagement.
Regulatory legal counsel and compliance teams rely on Pink Sheet to track guidance, rulemaking, and enforcement trends across agencies.
Access teams use Pink Sheet to connect regulatory decisions to pricing, reimbursement, and health technology assessment implications.
Development leaders track pathway designations, advisory committee trends, and inspection expectations affecting their programs.
Regulatory consultants and law firms cite Pink Sheet as a primary source in client advisory work, filings, and regulatory strategy documents.
Citeline’s award-winning publications provide in-depth coverage of the pharmaceutical industry, thanks to 40+ in-house journalists who tackle the tough issues with precision, persistence, and passion.
Pink Sheet has reporters in capital cities across three continents — Washington, Brussels, and other key regulatory hubs — with direct access to FDA, EMA, and other global agencies.
Pink Sheet’s global team of journalists tracks every marketing application from submission to approval, helping subscribers understand the shifting policies and procedures needed to get innovative drugs cleared in all major markets.
Pink Sheet is Norstella’s essential regulatory intelligence resource for life sciences professionals. It delivers authoritative reporting, in-depth policy analysis, and exclusive interviews with key decision-makers — covering FDA, EMA, MHRA, and other global agencies since 1939.
Unlike headline-driven news outlets, Pink Sheet’s reporters have direct access to FDA commissioners, CDER/CBER leadership, EMA officials, and Capitol Hill staff. Coverage explains what each regulatory development means for approvals, compliance strategy, and stakeholder management — not just what happened.
Pink Sheet includes trackers for FDA Advisory Committee Meetings, PDUFA dates, CBER & CDER Novel Approvals, Breakthrough, QIDP & RMAT Designations, Complete Response Letters, EU Performance, EU Accelerated Assessment, EU CHMP Opinions, EU PRIME Scheme, US & EU Biosimilars, and guidances from around the globe.
Pink Sheet is read by regulatory affairs leaders, government policy teams, legal and compliance professionals, market access strategists, and clinical operations executives. Every top 20 pharma company and leading regulatory consultancy subscribes.
Pink Sheet covers FDA, EMA, MHRA, and other agencies, with reporters in capital cities across three continents. Coverage includes in-depth analysis of global harmonization efforts, divergent national policies, and emerging regulatory trends across all major markets.
Contact us today to learn how we can support your pharmaceutical regulatory needs. Our team will be in touch shortly.
